DS
MRNA icon

David Shaw’s Moderna MRNA Stock Holding History

David Shaw’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.6M Sell
1,393,200
-1,023,800
-42% -$53M 0.05% 461
2026
Q1 		$123M Sell
2,417,000
-1,694,100
-41% -$79M 0.07% 308
2025
Q4 		$121M Sell
4,111,100
-223,600
-5% -$6.07M 0.07% 347
2025
Q3 		$112M Buy
4,334,700
+552,000
+15% +$15.4M 0.06% 365
2025
Q2 		$104M Buy
3,782,700
+406,200
+12% +$10.7M 0.07% 320
2025
Q1 		$95.7M Buy
3,376,500
+1,415,900
+72% +$50.2M 0.09% 292
2024
Q4 		$81.5M Buy
1,960,600
+912,500
+87% +$43.6M 0.06% 389
2024
Q3 		$70M Buy
1,048,100
+155,700
+17% +$14.3M 0.06% 385
2024
Q2 		$106M Sell
892,400
-35,900
-4% -$4.54M 0.1% 235
2024
Q1 		$98.9M Buy
928,300
+230,900
+33% +$23.3M 0.08% 265
2023
Q4 		$69.4M Buy
697,400
+190,100
+37% +$16M 0.06% 374
2023
Q3 		$52.4M Buy
507,300
+91,000
+22% +$10.2M 0.05% 411
2023
Q2 		$50.6M Sell
416,300
-90,500
-18% -$12.1M 0.05% 427
2023
Q1 		$77.8M Buy
506,800
+196,900
+64% +$32.5M 0.08% 284
2022
Q4 		$55.7M Sell
309,900
-57,900
-16% -$9.47M 0.06% 386
2022
Q3 		$43.5M Buy
367,800
+15,100
+4% +$2.29M 0.05% 455
2022
Q2 		$50.4M Sell
352,700
-168,600
-32% -$24.1M 0.06% 389
2022
Q1 		$89.8M Buy
521,300
+51,000
+11% +$8.59M 0.08% 270
2021
Q4 		$119M Sell
470,300
-235,300
-33% -$68.8M 0.1% 218
2021
Q3 		$272M Buy
705,600
+171,600
+32% +$63.3M 0.25% 56
2021
Q2 		$125M Buy
534,000
+189,600
+55% +$33.9M 0.11% 205
2021
Q1 		$45.1M Buy
344,400
+195,900
+132% +$28.4M 0.04% 531
2020
Q4 		$15.5M Buy
148,500
+18,100
+14% +$1.83M 0.01% 1095
2020
Q3 		$9.23M Sell
130,400
-228,600
-64% -$15.9M 0.01% 1292
2020
Q2 		$23.1M Buy
+359,000
New +$19.7M 0.03% 708

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

David Shaw's MRNA Position: Q2 2026 in Review

David Shaw reduced its Moderna (MRNA) stake by 96% in Q2 2026, selling an estimated $33.2M and leaving 24,951 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3317.

David Shaw first reported a position in MRNA in Q2 2019 and has held it in 27 quarters since. The position peaked at $393M in Q2 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • David Shaw held 24,951 shares of Moderna worth $1.75M as of Q2 2026.
  • David Shaw sold 641,581 Moderna shares in Q2 2026, an estimated $33.2M.
  • Moderna made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3317 holding.
  • David Shaw first reported a position in Moderna in Q2 2019 and has held it in 27 quarters since.
  • David Shaw's Moderna position peaked at $393M in Q2 2021.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.